Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2003

View Archived Issues

IDM exercises option to license cancer epitopes from Epimmune

New inverse agonist at alpha2-adrenoceptors enhances cognition in rats

Use of dopamine D3 agonists in sexual dysfunction

ARYx describes novel delivery systems for analgesics

Novel Wyeth compounds that increase HDL cholesterol

Shire BioChem designs series for Flavivirus infections

Inhibitors of beta-secretase claimed for Rx of Alzheimer's disease and related disorders

Agents for herpesvirus infections reported in recent patent

First European approval for a drug to reduce risk of suicidal behavior

Novocell encapsulated islet cell implants successful in diabetic primates

Multikine may enhance success of radiation and chemotherapy in H&N cancer

Updated GOLD guidelines for COPD treatment include first-line tiotropium

CG-5601, a potential alternative to thalidomide for ocular inflammation

Evidence of antitumor efficacy found for PDX in NSCLC

FDA requests additional data for Follistim

DOR BioPharma executes worldwide license agreement for rights to ricin vaccine technology

Repaglinide vs. nateglinide in combination with metformin for type 2 diabetes

FDA advisory committee hands down positive opinion for Crestor

Pralnacasan phase IIb clinical trial begins enrollment

Preliminary findings reveal troponin I suppresses genes associated with angiogenesis

Potential residual effects described for rivastigmine in Alzheimer's disease after discontinuation

FibroGen awarded grant to develop cancer therapies

Myriad Genetics collaborates with the Mayo Clinic to develop novel Alzheimer's drugs

Clinical efficacy of tetrathiomolybdate in advanced kidney cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...